Live Breaking News & Updates on Akeso inc

Stay updated with breaking news from Akeso inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC

Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

United-states , Canada , Japan , Australia , China , Chinese , National-comprehensive-cancer-network , Chinese-society-of-clinical-oncology , China-national-medical-products-administration , Drug-administration , Akeso-inc

Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA

Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

Australia , Canada , Japan , United-states , China , National-center , Akeso-inc , Drug-evaluation , State-drug-administration , New-drug-application , Summit-therapeutics

Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Akeso Inc. , a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines...

Hong-kong , China , Prnewswire-akeso-inc , Akeso-inc , National-center , New-drug-application , Drug-evaluation , State-drug-administration , Summit-therapeutics , Main-board , Stock-exchange

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors

Major players in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market are Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La...

Germany , Japan , Akeso , Indonesia-general- , Indonesia , United-kingdom , China , New-york , United-states , Australia , South-korea , India

Reviewing Alimera Sciences (NASDAQ:ALIM) and Summit Therapeutics (NASDAQ:SMMT)

Alimera Sciences (NASDAQ:ALIM – Get Free Report) and Summit Therapeutics (NASDAQ:SMMT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk. Profitability This table compares Alimera Sciences and […]

United-kingdom , Massachusetts , United-states , Georgia , Cambridge , Cambridgeshire , Alpharetta , Alimera-sciences , Summit-therapeutics-inc , Eyepoint-pharmaceuticals-us-inc , Alimera-sciences-inc

Summit Therapeutics (NASDAQ:SMMT) versus Alimera Sciences (NASDAQ:ALIM) Financial Survey

Summit Therapeutics (NASDAQ:SMMT) versus Alimera Sciences (NASDAQ:ALIM) Financial Survey
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Alpharetta , Georgia , United-states , Cambridge , Cambridgeshire , Massachusetts , Summit-therapeutics-inc , Alimera-sciences-inc , Akeso-inc , Alimera-sciences

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Australia , China , Hong-kong , Canada , Japan , Akeso-inc , Prnewswire-akeso-inc , Summit-therapeutics , Main-board , Stock-exchange

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023

Promising Updated Phase II Data Presented at ASCO 2023 for Ivonescimab


First US Patient Treated in Ivonescimab Phase III Clinical Trial with the First Patient in Ivonescimab's Second Phase III...

United-kingdom , China , Canada , Japan , Australia , Menlo-park , California , United-states , American , Chinese , Team-summit

Akeso Inc. Published 2023 Interim Results Positive Profit Alert

/PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing...

Canada , China , Japan , Akeso-inc , Company-for-the-reporting-period , Prnewswire-akeso-inc , Reporting-period , Summit-therapeutics , Akeso , Nc- ,